Insider
Novo Nordisk A SNVO

Novo Nordisk reports Q3 earnings and asset impairments

Novo Nordisk reported its third-quarter 2026 results, with adjusted operating profit increasing by 27% to 31.72 billion Danish kroner (DKK). However, reported operating profit fell by 9% due to 8.7 billion DKK in asset impairment charges, reflecting costs for manufacturing reorganization and the development of ziltivekimab.

Verified against 2 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
a long hallway with pictures on the walls
Photo by zhang shuaizhang on Unsplash
27%
Adjusted operating profit increase
9%
Reported operating profit decrease
8.7 billion DKK
Asset impairment charges

Key points

  • The company's reported operating profit for the third quarter of 2026 fell by 9% year-over-year.
  • The oral Wegovy pill showed strong demand, generating 5.39 billion DKK in revenue during the third quarter of 2026.
  • As of November 2, 2026, Novo Nordisk is continuing its share repurchase program initiated on May 6, 2026.

Financial results and asset impairments

The company's reported operating profit for the third quarter of 2026 fell by 9% year-over-year. This figure includes non-cash impairment charges: 4.6 billion DKK related to the ziltivekimab project and 4.1 billion DKK for manufacturing network optimization.

Portfolio development and clinical trials

The oral Wegovy pill showed strong demand, generating 5.39 billion DKK in revenue during the third quarter of 2026. Total prescriptions for the drug have exceeded 8 million since its launch.

Clinical trial results were mixed: CagriSema showed success in the REDEFINE 9 and REIMAGINE 5 studies. Meanwhile, the ZEUS and HERMES trials for ziltivekimab did not meet primary endpoints, while the HIBISCUS trial for Etavopivat was successfully completed.

Share repurchases

As of November 2, 2026, Novo Nordisk is continuing its share repurchase program initiated on May 6, 2026. Since February 4, 2026, the company has repurchased 41,714,179 B shares for a total of 11.56 billion DKK.

Key focus areas

Investors should monitor future financial reports to see if additional manufacturing reorganization costs emerge, which could impact future earnings.

Original sources

  1. 6-K filing, November 3, 2026November 3, 2026SHA-256 of our archived copy 3c411e9e8041…
  2. 6-K filing, November 4, 2026November 4, 2026SHA-256 of our archived copy 4f60172ef25a…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards